Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

clearcreekbio.com

Founded Year

2017

Stage

Series A | Alive

Total Raised

$7.15M

About Clear Creek Bio

Clear Creek Bio develops therapies that overcome differentiation blockade in cancer. It does so using biomarkers to ensure that each patient gets the right drug at the right dose.

Clear Creek Bio Headquarters Location

585 Massachusetts Avenue 4th Floor

Cambridge, Massachusetts, 02139,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Clear Creek Bio

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Clear Creek Bio is included in 2 Expert Collections, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Clear Creek Bio Patents

Clear Creek Bio has filed 13 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Experimental cancer drugs
  • Oncology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/4/2020

1/25/2022

Prodrugs, Transcription factors, Experimental cancer drugs, Acute myeloid leukemia, Metabolism

Grant

Application Date

12/4/2020

Grant Date

1/25/2022

Title

Related Topics

Prodrugs, Transcription factors, Experimental cancer drugs, Acute myeloid leukemia, Metabolism

Status

Grant

Latest Clear Creek Bio News

Clear Creek Bio Advances Its Highly Potent SARS-CoV-2 PLpro Inhibitors in Discovery of an Oral Direct-Acting Antiviral to Treat COVID-19

Jan 6, 2022

Clear Creek Bio signed a CRADA with the NIH to support its SARS-CoV-2 PLpro inhibitor discovery This CRADA was initiated as part of the Antiviral Program for Pandemics (APP) Via APP, Clear Creek will be able to use the NIH’s current and expanded contract resources and NCATS laboratories to prioritize the advancement of antiviral candidates and de-risk early-stage development January 06, 2022 09:00 AM Eastern Standard Time CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Clear Creek Bio, Inc. announced today that the company has signed a Cooperative Research and Development Agreement (CRADA) with the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) to identify and develop a SARS-CoV-2 papain-like protease (PLpro) inhibitor. PLpro is an essential coronavirus enzyme involved in viral replication and regulates host innate immune responses to viral infection. The potent PLpro inhibitors developed by Clear Creek Bio have attractive drug properties, and this CRADA will support development of the most promising candidates, including completing IND-enabling studies. The SARS-CoV-2 virus has caused the deaths of more than 800,000 people in the United States and more than 5 million globally. Despite worldwide efforts, a strong medical need remains for safe and effective, orally available, direct-acting antiviral agents for the treatment of SARS-CoV-2 infections. The continuing emergence of new variants that challenge existing therapies further underscores this need for additional treatments. “There’s a critical need for widespread availability of highly effective oral antivirals that can be taken at home early in the course of infection, significantly reduce transmission of the virus and prevent overwhelming surges in hospitalizations, ultimately saving lives,” said Nadim Shohdy, Ph.D., Vice President for Corporate Development at Clear Creek Bio. “It’s clear that we will need direct-acting antivirals against multiple SARS-CoV-2 targets to combat variant-driven resistance.” “PLpro is a promising target for therapeutic intervention against COVID-19 because of its potential for dual effects—blocking SARS-CoV-2 replication and promoting antiviral immunity,” said Vikram Sheel Kumar, M.D., Chief Executive Officer of Clear Creek Bio. “We have potent inhibitors that we are excited to advance and expand under this collaboration with NCATS.” About Clear Creek Bio Clear Creek Bio is a private, clinical-stage biotechnology company with a mission to develop therapies that meet the global need for safe, effective, and easy-to-administer antivirals. Clear Creek Bio is focused on host-targeting and direct-acting small molecule antiviral therapeutics targeting SARS-CoV-2 and other medically important viruses. The Company’s first drug candidate, brequinar, has potent antiviral activity against a wide range of viruses, including SARS-CoV-2, and is presently being studied in a Phase 2 clinical trial for treatment of SARS-CoV-2 infection. For additional information, please visit www.clearcreekbio.com . Contacts

Clear Creek Bio Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Clear Creek Bio Rank

  • When was Clear Creek Bio founded?

    Clear Creek Bio was founded in 2017.

  • Where is Clear Creek Bio's headquarters?

    Clear Creek Bio's headquarters is located at 585 Massachusetts Avenue, Cambridge.

  • What is Clear Creek Bio's latest funding round?

    Clear Creek Bio's latest funding round is Series A.

  • How much did Clear Creek Bio raise?

    Clear Creek Bio raised a total of $7.15M.

  • Who are the investors of Clear Creek Bio?

    Investors of Clear Creek Bio include Biogen Idec New Ventures and RA Capital Management.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.